Video MD - Excellence in Physician-Patient Education
  • En Espanol
  • Home
  • About Us
  • Communities
  • Create Account
  • Sign In
  • All Conditions
    • Allergy (36)
    • Alternative Medicine (37)
    • Arthritis (39)
    • Back Pain (34)
    • Cancer (184)
    • Cholesterol (33)
    • Current Controversies (64)
    • Dental (40)
    • Dermatology (97)
    • Diabetes (55)
    • Endocrine Disorders (17)
    • ENT-ear,nose and throat (57)
    • Exercise/Rehabilitation (77)
    • Eye care (58)
    • FDA Warnings (11)
    • Gastroenterology (114)
    • General Medicine (111)
    • Geriatrics (28)
    • Heart Disease (189)
    • See All Conditions

Dr. Elliott Vichinsky on Jadenu

Home > Hematology > Dr. Elliott Vichinsky on Jadenu
Get the Flash Player to see this player.
Rate: (Click the stars to rate)
     

Published on Mar 31, 2015 by MultiVu, Views: 3185

Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.

Tweet
Display VideoMD at Your Practice

Video MD does not provide medical advice, diagnosis or treatment.
Bookmark and Share
Featured Videos |Press Releases & News |Terms |Privacy Policy |Contact Us |Sitemap
© Copyright 2021 www.videomd.com